Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myotonin-protein kinase (DMPK) is a non-receptor serine/threonine protein kinase primarily expressed in skeletal, cardiac, and smooth muscle tissues, where it plays a critical role in maintaining muscle structure, ion homeostasis, and cardiac conduction. The DMPK gene is the genetic locus for myotonic dystrophy type 1 (DM1), an autosomal dominant neuromuscular disorder caused by an abnormal expansion of CTG trinucleotide repeats in the 3' untranslated region (3' UTR) of the gene. This expansion leads to the transcription of toxic mutant DMPK mRNAs containing long CUG repeats, which accumulate in nuclear foci and sequester essential RNA-binding proteins, particularly muscleblind-like (MBNL) splicing factors. The resulting loss of free MBNL proteins causes widespread alternative splicing defects (spliceopathy) that drive the clinical manifestations of DM1, including myotonia, muscle wasting, and cardiac arrhythmias. Therapeutic strategies targeting DMPK focus on reducing the levels of these toxic transcripts using RNA-targeted modalities, such as antibody-oligonucleotide conjugates (AOCs) like delpacibart etedesiran (del-desiran) and zeleciment basivarsen (z-basivarsen), which deliver small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) to degrade mutant DMPK mRNA and restore normal splicing.
siRNA-mediated degradation of DMPK mRNA, Antisense oligonucleotide (ASO)-mediated RNase H cleavage of DMPK mRNA, and steric blocking of CUG repeats on DMPK mRNA
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myotonin-protein kinase (DMPK).